Affiliation:
1. Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao 266003, China
2. Department of Central Laboratory, the Affiliated Hospital of Qingdao University, Qingdao 266003, China
3. Department of Oncology, Chinese Medical Hospital of Huangdao District, Qingdao 266003, China
Abstract
Abstract
Objective
To investigate the mechanism of low-dose fractionated radiation on reversing cisplatin resistance in ovarian carcinoma via vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) in vivo.
Methods
Human cisplatin-resistant ovarian carcinoma cells (SKOV3/DDP) were injected into nude mice to establish ovarian cancer xenografts. The mice were randomly divided into three groups: a control group, a low-dose fractionated radiation (LDRFT) group, and a conventional-dose radiation group. Each group was exposed to 0 cGy, 50 cGy, and 200 cGy radiation, respectively, for 4 weeks, up to a total of 8.0 Gy. Mice in the LDFRT group were irradiated twice daily with 6 hour intermissions on day 1 and 2 of every week for a total of 4 weeks. Conventional-dose group mice were given a single 200 cGy radiation dose on the first day each week for a total of 4 weeks. Maximum horizontal and vertical diameters of the tumors were measured every other day and used to create a tumor growth curve. After 4 weeks of irradiation, we dissected the tumor tissue and calculated the tumor inhibition rate. RT-PCR detected the expression of VEGF and mTOR, and Western blots detected the expression of corresponding proteins.
Results
Both LDRFT and conventional-dose radiation inhibited the growth of tumor cells, and growth of tumors in the two radiation groups compared with growth in the control group were significantly different (P < 0.05). The rate of tumor inhibition in the LDFRT group (37.5603%) was lower than in the conventionaldose group (47.4446%), but there was no significant difference (P > 0.05). Compared with the other two groups, the mRNA expression of VEGF was significantly lower in the LDFRT group (P < 0.05), but there was no obvious difference between the conventional-dose and control groups. There was no obvious difference in the mRNA expression of mTOR among the three groups, but the expression of the protein p-mTOR was lower in the LDFRT group (P < 0.05), as confirmed by Western blotting.
Conclusion
LDFRT is as effective at inhibiting the growth of tumor cells as conventional-dose radiation. In addition, LDFRT could deregulate the expression of VEGF and p-mTOR, and may therefore play a vital role in reversing cisplatin resistance in ovarian cancer.
Publisher
Ovid Technologies (Wolters Kluwer Health)